EHNA hydrochloride (Synonyms: erythro-9-(2-Hydroxy-3-nonyl)adenine) |
| Katalog-Nr.GC10935 |
EHNA-Hydrochlorid ist ein potenter und selektiver dualer Inhibitor der zyklischen Nukleotid-Phosphodiesterase 2 (PDE2) (IC50=4 μM) und der Adenosindeaminase (ADA).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 58337-38-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
EHNA is a reversible adenosine deaminase inhibitor (IC50 = 1.2 μM in human red blood cells) that also selectively inhibits the cGMP-specific phosphodiesterase (PDE2) (IC50s = 0.8 and 2 μM from human and porcine myocardium, respectively, 3.5 μM in rat hepatocyte, and 5.5 μM in human platelet).[1],[2] Comparatively, EHNA is much less potent at inhibiting PDE1, PDE3, or PDE4 (IC50s > 100 μM).1 EHNA has been used to evaluate cardioprotective and neuroprotective effects during ischemia, to study the role of cAMP/cGMP signaling, and to maintain pluripotency/prevent differentiation of human embryonic stem cells.[3],[4][5]
Reference
[1]. Podzuweit, T., Nennstiel, P., and Müller, A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell. Signal. 7(7), 733-738 (1995).[
[2]. Michie, A.M., Lobban, M., Müller, T., et al. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell. Signal. 8(2), 97-110 (1996).
[3]. Barankiewicz, J., Danks, A.M., Abushanab, E., et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J. Pharmacol. Exp. Ther. 283(3), 1230-1238 (1997).
[4]. Dickinson, N.T., Jang, E.K., and Haslam, R.J. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation. Biochem. J. 323(Pt. 2), 371-377 (1997).
[5]. Burton, P., Adams, D.R., Abraham, A., et al. Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochem. J. 432(3), 575-584 (2010).
| Cas No. | 58337-38-5 | SDF | |
| Überlieferungen | erythro-9-(2-Hydroxy-3-nonyl)adenine | ||
| Chemical Name | (2R,3S)-3-(6-amino-9H-purin-9-yl)nonan-2-ol hydrochloride | ||
| Canonical SMILES | O[C@H](C)[C@H](CCCCCC)N1C2=NC=NC(N)=C2N=C1.Cl | ||
| Formula | C14H23N5O.HCl | M.Wt | 313.83 |
| Löslichkeit | 30mg/mL in DMSO, 30mg/mL in DMF, 20mg/mL in Ethanol, 10mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1864 mL | 15.9322 mL | 31.8644 mL |
| 5 mM | 0.6373 mL | 3.1864 mL | 6.3729 mL |
| 10 mM | 0.3186 mL | 1.5932 mL | 3.1864 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *